AR and neoplasm: Due to these activities against ERα, patients with an ERα+ve/AR+ve phenotype would have relatively better clinical features, e.g., smaller tumor [22,23], and longer survival time indicated by disease-free survival (DFS), overall survival (OS) and recurrence-free survival (RFS) [24,25,26].